Alloksys Life Sciences starts phase 2 trial

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Theratase plc said Monday that a new Dutch biotech company, Alloksys Life Sciences BV, has started phase 2 clinical trials on patients undergoing coronary artery bypass graft surgery.

The patients will receive an infusion of alkaline phosphatase in a drug form developed and formulated by Biozyme Laboratories, a division of Theratase, starting just prior to anaesthesia.

The objective of the study is to reduce post surgical inflammatory responses and thereby improve well-being and reduce overall hospital length of stay.

Theratase, a manufacturer of specialist enzymes to the medical diagnostics industry, said the market in the United States is about $300 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.